Skip to main content

Latest

In The Trenches

Medical marijuana group moves to hasten outcome in federal lawsuit

For immediate release: May 24, 2007 Contact: ASA Legal Campaign Director Kris Hermes at 510-251-1856 x307 or ASA Chief Counsel Joe Elford at 415-573-7842 Medical marijuana group moves to hasten outcome in federal lawsuit Patients file motion for summary judgment today to correct government misinformation San Francisco, CA – A national medical marijuana patients’ rights group filed a motion for summary judgment today in its lawsuit against the federal government in an attempt to accelerate a decision in the case. The plaintiff, Americans for Safe Access (ASA), filed a lawsuit in February 2007 challenging statements by the federal Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) that marijuana has no accepted medical value. The lawsuit followed a two-year administrative petition process using a little-known law called the Data Quality Act (DQA), which allows parties to challenge the science used in regulatory policy. By filing the motion for summary judgment, ASA will force the case to be heard in roughly 90 days. This rare legal move, where judgment is requested from the court before the government has a chance to answer the lawsuit complaint, indicates confidence in the amount of scientific evidence demonstrating marijuana’s medical efficacy. “We are taking an aggressive legal approach for two reasons,” said ASA Chief Counsel Joe Elford. “Not only do we believe we have science on our side, but by quickening the pace with which the federal government recognizes that science,, seriously ill persons who might benefit from medical marijuana will no longer be discouraged from using it.” The exhibits filed in support of the motion for summary judgment include more than a dozen domestic and international peer-reviewed scientific studies that show the effectiveness of marijuana in treating pain, nausea, muscle spasticity, and many other conditions. The evidence provided by ASA is meant to refute claims by the federal government that “there have been no studies that have scientifically assessed the efficacy of marijuana for any medical condition.” (66 Fed.Reg. 20038, 20052; April 18, 2001.) In addition to the overwhelming evidence, a lack of disputed facts will also help to secure a speedy decision by the court. The plaintiff’s case was affirmed by a recent editorial in Science Magazine, a publication of the American Association for the Advancement of Science, which posited that HHS had “violated its own DQA guidelines.” The Science editorial followed a February publication by the peer-reviewed journal Neurology of a human trials study in the U.S. clearly showing that marijuana relieved neuropathic pain in people living with HIV/AIDS. If successful, ASA’s case will be the first in which a court has recognized the necessity of reviewing disputes filed under the DQA. Two other courts have already denied review in lawsuits filed under the Act by large corporations. Review the Motion for Summary Judgment at http://www.safeaccessnow.org/downloads/DQA_Summary_Judgment_Motion.pdf. Review info on the Data Quality Act and ASA’s lawsuit against the federal government at http://www.safeaccessnow.org/article.php?list=type&type=160. # # # With over 30,000 active members in more than 40 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.
Event

Talk: A Changing View of Drugs in Society

The view on drugs is changing around the globe. Join us in a session that explores the controversial new public health model that challenges the fundamentals of drug prohibition. Topics include:
Chronicle
Event

Alabama Townhall meeting on Discriminatory Federal Drug Sentencing

The ACLU Washington Legislative Office and the ACLU of Alabama will host a townhall meeting in Birmingham, Alabama on the need to repair the current discriminatory federal drug sentencing policy. The event is open to the press, and ACLU speakers will be available afterwards for interviews.
Event
Chronicle
Blog

Goodbye, Dr. Tod

I am sad to report the passing of Dr. Tod Mikuriya, a leading and long-time advocate for medical marijuana, scientific and historical marijuana researcher, physician and drug policy reformer. Tod was a member of DRCNet's advisory board and a long-time friend. Phil has written a memorial to Tod for this week's Chronicle, and I am also posting it here. Click the "read full post" link below, if you don't already see it, or read it online here. Tod Mikuriya addressing a NORML conference
Chronicle
Chronicle
Chronicle
Blog

Can You Smell the Meth?

This story might take first prize in a week already marred by frivolous lawsuits and other stupid drug-related news:
A deputy U.S. marshal based in Charleston is suing the makers of the popular cold remedy Zicam over his lost sense of smell, which he says has put him in danger of being unknowingly exposed to methamphetamine labs.
…

As a federal law enforcement officer, he said his duties sometimes expose him to methamphetamine labs, which are considered dangerous to be in contact with. [Charleston Daily Observer]
Come to think of it, I too am deeply concerned about being exposed to highly-toxic meth labs. Who shall I sue? Perhaps the shortsighted legislators who've created a black market and ensured the continued illicit production of methamphetamine in our communities.

And before we get too excited about this cool drug that prevents cops from smelling things, note that Zicam's manufacturer says this is nonsense. They claim that allegations of smelling-loss occur because Zicam is a cold medicine popular among people with horrible pre-existing respiratory problems.

Sounds plausible enough, but good luck explaining "correlation is not causation" to a drug warrior.